Nektar Therapeutics (ETR:ITH0)

Market Cap	1.23B +25.3%
Revenue (ttm)	47.78M -27.2%
Net Income	-137.53M
EPS	-5.66
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	85
Open	35.40
Previous Close	36.06
Day's Range	34.94 - 35.75
52-Week Range	34.94 - 66.72
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 11, 2026

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has col...

• Industry: Pharmaceutical Preparations
• Founded: 1990
• Employees: 63
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: ITH0

Financial Performance

In 2025, Nektar Therapeutics's revenue was $55.23 million, a decrease of -43.89% compared to the previous year's $98.43 million. Losses were -$164.08 million, 37.9% more than in 2024.

Financial numbers in USD

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 8, 2026

Data Sources Report a data error